Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Promimic AB is a pioneering biotechnology company focused on the development and commercialization of nanosurface solutions for the medical implant industry. At the heart of its innovative offerings is a proprietary surface enhancement technology designed to improve osseointegration, making implants bioactive and fostering better integration with human bone tissue. This technology is essential in sectors such as orthopedics, dental, and other implant markets, where effective and quick incorporation into the body’s natural bone structure is critical for patient outcomes. Promimic AB's nanosurface solutions are not only enhancing the efficacy of existing implant designs but also facilitating the development of new, advanced medical devices. This positions the company as a crucial player in the healthcare and biotechnology industries, where there is a continuous push for improving the quality of patient care through technological advancements. With its commitment to elevating medical implant functionality, Promimic AB plays a significant role in advancing medical treatment options and improving the success rates of surgical procedures worldwide.
kr 0.91
+kr 0.00 (+0.00%)
EOD Jun 25, 2026 · Twelve Data
The business is unprofitable at the operating level (-20.88% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue growth slowed to 1.0%, essentially flat. This is a business that needs a catalyst.
Negative free cash flow of -kr 13M. The business is consuming cash, not generating it.
0.3x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 44M
▲ +1.0% YoY
Net Income (TTM)
-kr 8M
▲ +30.3% YoY
Op. Margin
-19.19%
▼ -0.9pp YoY
ROIC
-11.36%
▼ -1.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 4M
▲ +36.1% YoY
Op. Cash Flow (TTM)
-kr 4M
▲ +41.9% YoY
Net Debt
-kr 21M
Net Cash Position
Cash & Equiv.
kr 21M
3Y CAGR: +39.9%
Continue Research
At a P/E of 0.3, Promimic AB (PRO.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Promimic AB scores 50/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Promimic AB scores 50 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -19.2% operating margin and a -11.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh PRO.XSTO's valuation and scores 50/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.